Early Start of Infliximab in Crohn's Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort.
Fabian SchnitzlerTheresia SeitzCornelia Tillack-SchreiberSilke LangeConstanze WaggershauserThomas OchsenkühnPublished in: Crohn's & colitis 360 (2021)
Our data on early IFX therapy in CD support early IFX intervention with more patients achieving ER, and less patients developing stricturing disease behavior. Early IFX intervention could therefore change the course of CD.
Keyphrases
- end stage renal disease
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cells
- mental health
- patient reported outcomes
- rheumatoid arthritis
- ultrasound guided
- electronic health record
- disease activity
- endoplasmic reticulum
- breast cancer cells